Bank Of New York Mellon Corp Atea Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$3.0 - $4.97 $928,677 - $1.54 Million	309,559 New	309,559 $1.04 Billion
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $1.39 Million - $1.98 Million	320,546 New	320,546 $1.54 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $202,097 - $323,577	36,812 Added 13.63%	306,856 $1.75 Million
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $35,615 - $54,658	-6,682 Reduced 2.41%	270,044 $1.92 Million
Q1 2022 May 11, 2022	SELL	$5.5 - $9.19 $5,868 - $9,805	-1,067 Reduced 0.38%	276,726 $2 Million
Q4 2021 Feb 11, 2022	BUY	$7.67 - $44.59 $142,040 - $825,762	18,519 Added 7.14%	277,793 $2.48 Million
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $1.34 Million - $2.21 Million	62,999 Added 32.1%	259,274 $9.09 Million
Q2 2021 Aug 11, 2021	BUY	$19.22 - $59.08 $2.92 Million - $8.98 Million	152,038 Added 343.69%	196,275 $4.22 Million
Q1 2021 May 13, 2021	BUY	$41.42 - $88.44 $307,253 - $656,047	7,418 Added 20.15%	44,237 $2.73 Million
Q4 2020 Feb 09, 2021	BUY	$26.36 - $41.78 $970,548 - $1.54 Million	36,819 New	36,819 $1.54 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.